High levels of tumor-infiltrating lymphocytes (TILs) are associated with higher pCR rates after preoperative chemotherapy plus HER2-targeted neoadjuvant treatment [46,47,48] and improved outcomes (overall survival (OS)) with chemotherapy plus HER2-targeted therapy in patients with ABC [49]. This evidence concerns the gene ERBB2 and aneurysmal bone cyst.